



**BioMarker**  
STRATEGIES

## ***News Release***

---

**Contact:**

**Scott Allocco, President**

**410-522-1008**

**[sallocco@biomarkerstrategies.com](mailto:sallocco@biomarkerstrategies.com)**

**FOR IMMEDIATE RELEASE**

Wednesday, September 28, 2011 at 8am

***National Cancer Institute Awards Companion Diagnostic Development Contract to BioMarker Strategies***

*Company also announces additional investments of \$2.3 million*

Baltimore, MD—September 28 —BioMarker Strategies announced today that the National Cancer Institute (NCI) has awarded the company a Small Business Innovative Research (SBIR) contract to develop a pathway-based companion diagnostic test for drug inhibitors targeting the ErbB signal transduction network. The NCI awarded Phase 1 funding of \$200,000. The company will be eligible to apply for Phase 2 funding of \$1.5m if the first phase is successfully completed. The company also announced, in an SEC regulatory filing, that the company raised more than \$2.3 million from investors during the month of August.

The company will use funding from this SBIR award and its investors to expand its predictive test development program for use in its automated SnapPath™ live tumor cell testing system. Under this award, initial tumor types will include melanoma and breast cancer. In the SnapPath™ device, live tumor cells from human biopsies are stimulated to evoke phosphoprotein-based Functional Signaling Profiles (FSP) that are not possible in dead, fixed tumor tissue. These profiles will assist oncologists in determining which targeted drug treatments, or classes of targeted drugs, will benefit their cancer patients. In their program announcement, the NCI sought proposals that “stimulate research, development, and commercialization of innovative tests and technology platforms” for all types of companion diagnostic applications.

“This additional funding will help us to expand our predictive test development pipeline, which includes companion diagnostics for drugs targeting the ErbB signaling network that includes a large number of the targeted cancer drugs under development today,” said Dr. Douglas Clark, Acting CEO of BioMarker Strategies. “This NCI award also signals the growing recognition that static, nucleic acid-based biomarkers will not be enough to predict patient response to drug therapies, and that new, pathway-based, approaches using living cells will be needed to enable personalized medicine for cancer.”

BioMarker Strategies is developing the SnapPath™ system to enable next-generation biomarker tests for cancer. The system incorporates an automated, live-tumor-cell processing device with first-in-class, functional, ex vivo biomarker tests to inform clinical decision making for targeted cancer therapeutics. SnapPath™, which was also developed with SBIR funding support from the NCI, stimulates a patient’s live tumor cells outside the body to obtain a pathway-based Functional Signaling Profile (FSP) of the signal transduction network. The company is located at the Johns

NEWS RELEASE

Hopkins Science + Technology Park in East Baltimore. For more information about BioMarker Strategies, refer to [www.biomarkerstrategies.com](http://www.biomarkerstrategies.com).

# # #

*Some of the information in this release contains our projections or other forward-looking statements regarding future events. We wish to caution you that these statements are only predictions and actual events or results may differ materially. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Forward-looking statements included herein are made as of the date hereof, and we undertake no obligation to update publicly such statements to reflect subsequent events or circumstances. Actual results could differ materially from anticipated results.*

# # #